Transglutaminase 2

Polyclonal antibody to human tissue transglutaminase (TG2)

500 µg 365 € available

Art. No. A014
Host Rabbit
Immunogen Human tissue transglutaminase (full length protein with N-terminal hexahistidin-tag) recombinantly produced in insect cells
Specificity Specificity of A014 was determined with human transglutaminases (TG1 – TG7, FXIII) and TG2 of different species.
A014 has no cross reactivity to TG1, TG6 and TG7 and very slight cross reactivity to TG3, TG4, TG5 and FXIII.
A014 also recognizes TG2 form various species, although at a lower signal intetnsity. Note: A014 also detects dog TG2.

The epitopes the polyclonal antibody to human TG2 binds to were determined using PEPperCHIP® Transglutaminase Microarray (P111).
A014 recognizes the epitopes Y149LDSE153, D242NNYGDGVSP251, N318EFGEIQG325, Q348PGYEG353, Q355ALDPTPQEK364, D438ITHT442, P446EGSSEEREAFT457, F492AHITNNTAEE502, L629TEEQ633, E637IPDPVEAG645

For more information klick here:
Poster presentation at GRC, 2016 (Girona, Spain)
Formulation The antibody is lyophilized from 200 μL 0.02 M Tris-HCl buffer pH 8.0, 0.028 M NaCl, 2 mg/mL human serum albumin, azide free.
Application Western-Blotting, immuno-fluorescence, immuno-histochemistry Note: For FACS antibody A028 (FITC-labeled A014) is recommended.
Storage Stable for a minimum of 2 years at –20°C as lyophilized powder
Delivery is possible at ambient temperature
Reference(s) Dulay et al., Biosens. Bioelectron. 2011, 26:3852-6
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA